Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer

What Was Tested

Researchers studied Triptorelin in this randomized controlled trial publication.

As a treatment goal, suppression of plasma testosterone levels to <50 ng/dl has been established over decades.

Why It Was Studied

Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC).

Who Took Part

According to the abstract, 920 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, men only.

Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.

Patients aged 42-96 years had to be eligible for ADT and to be either naïve to hormonal treatment or have undergone appropriate washout prior to enrolment.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Patients were treated with triptorelin SR formulations for 2-12 months.

Primary endpoints of this analysis were serum testosterone concentrations under treatment and success rates overall and per formulation, based on a testosterone target threshold of 20 ng/dl.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Hormonal, Biological Availability, Gonadotropin-Releasing Hormone, Neoplasm Staging, Prostate-Specific Antigen, Prostatic Neoplasms and Testosterone.

The authors tagged it with the keywords Advanced prostate cancer, Castration limits, Hormonal therapy, Testosterone suppression and Triptorelin.

What This Means in Plain Language

The paper is a randomized study of Triptorelin in 920 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Advances in therapy), a journal based in United States.

More context: the Triptorelin compound page, all human trials.